← Back to Search
Pharmacokinetics And Biodistribution Of RGD-targeted Doxorubicin-loaded Nanoparticles In Tumor-bearing Mice.
D. C. Bibby, J. Talmadge, Milind K. Dalal, S. G. Kurz, Kevin M. Chytil, S. Barry, David G. Shand, M. Steiert
Published 2005 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
We report the biodistribution and pharmacokinetics (PK) of a cyclic RGD-doxorubicin-nanoparticle (NP) formulation in tumor-bearing mice. The NP core was composed of inulin multi-methacrylate with a targeting peptide, cyclic RGD, covalently attached to the NPs via PEG-400. Seventy-two percent of the doxorubicin was attached to the NP matrix via an amide bond; 28% of doxorubicin was entrapped as unconjugated drug. The PK of total, unconjugated and metabolized doxorubicin was examined for 5 days following intravenous (i.v.) administration of the NP formulation (250 microg doxorubicin equiv.), revealing a bi-exponential fix with a terminal half-life of 5.99 h. In addition, the biodistribution studies revealed decreasing drug concentrations over time in the heart, lung, kidney and plasma and accumulating drug concentrations in the liver, spleen and tumor. The drug concentration in these latter tissues peaked between 24 and 48 h with the liver, spleen and tumor containing 56, 3.5 and 1.8% of the administered dose at t=48 h, respectively. In contrast to all of the organs studied, the tumors contained high levels of a doxorubicin metabolite.
This paper references
Screening for Biological Response Modifiers: Methods and Rationale
J. Talmadge (1985)
HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
M. Kovář (2003)
αv Integrins as receptors for tumor targeting by circulating ligands
R. Pasqualini (1997)
Acid pH in tumors and its potential for therapeutic exploitation.
I. Tannock (1989)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Heterogeneity of tumor cells from a single mouse mammary tumor.
D. Dexter (1978)
The role of anthracyclines in second‐line therapy of ovarian cancer
J. Vermorken (2003)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.
D. Gustafson (2002)
Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)
R. Duncan (1998)
Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-Adriamycin conjugates
G. Kwon (1994)
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
R. Hong (1999)
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.
R. Schiffelers (2003)
Are cancer cells acidic?
J. Griffiths (1991)
Cancer : Principles and Practice of Oncology
V. Devita (1982)
Characterization of the interaction of galactose-exposing particles with rat Kupffer cells.
J. Kuiper (1994)
The pharmacokinetics of polymer-bound adriamycin.
L. Seymour (1990)
Polymeric micelles for delivery of poorly water-soluble compounds.
G. Kwon (2003)
HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.
J. Kopeček (2000)
Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability.
F. Miller (1983)
HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
K. Ulbrich (2003)
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.
J. van Asperen (1998)
This paper is referenced by
Targeted Drug Delivery via the Use of ECM-Mimetic Materials
Jeongmin Hwang (2020)
Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects
Z. Song (2017)
Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN).
Yiguang Jin (2006)
Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior.
Chen Fang (2010)
Liver Cancer: Current and Future Trends Using Biomaterials
Sue Anne Chew (2019)
Role of nanotechnology in pharmaceutical product development.
H. Devalapally (2007)
Applications of Carbon-Based Nanomaterials for Drug Delivery in Oncology
N. Levi-Polyachenko (2008)
cRGD functionalised nanocarriers for targeted delivery of bioactives
K. R. Gajbhiye (2018)
Innovative Drug Delivery Systems for the Administration of Natural Compounds
D. Paolino (2007)
Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery Applications
Saurabh Bhatia (2016)
Latex nanoparticles for multimodal imaging and detection in vivo
R. Cartier (2007)
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Rajni Sinha (2006)
RGD-HK Peptide-Functionalized Gold Nanorods Emerge as Targeted Biocompatible Nanocarriers for Biomedical Applications
Sohameh Mohebbi (2019)
In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectors
Zhao-hui Jin (2007)
Integrin Targeted Delivery of Radiotherapeutics
Z. Liu (2011)
Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity.
Ahmed M Al-Abd (2013)
Synthesis and Evaluation of a Triblock Copolymer/ZnO Nanoparticles from Poly(ε-caprolactone) and Poly(Acrylic Acid) as a Potential Drug Delivery Carrier.
Lida Ahmadkhani (2017)
Radioimmunonanoparticles for Cancer Imaging and Therapy
A. Natarajan (2011)
Polymeric Conjugates for Angiogenesis-Targeted Tumor Imaging and Therapy
A. Mitra (2006)
The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo.
S. Kennel (2008)
Cancer Laser Thermotherapy Mediated by Plasmonic Nanoparticles
G. Terentyuk (2010)
In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice.
V. Hanušová (2013)
Understanding the particokinetics of engineered nanomaterials for safe and effective therapeutic applications.
M. Zhu (2013)
Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy
S. Dey (2009)
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
L. E. V. Vlerken (2007)
A Novel Lipid-based Nanotechnology Platform For Biomedical Imaging And Breast Cancer Chemotherapy
Adam J Shuhendler (2013)
In Vivo Evaluation of Doxorubicin-Loaded (PEG)3-PLA Nanopolymersomes (PolyDoxSome) Using DMBA-Induced Mammary Carcinoma Rat Model and Comparison with Marketed LipoDox™
Wubeante Yenet Ayen (2012)
Self-assembled drug delivery systems 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation.
Yiguang Jin (2008)
Doxorubicin conjugates for selective delivery to tumors.
J. Florent (2008)
Leucine-Aspartic Acid-Valine Sequence as Targeting Ligand and Drug Carrier for Doxorubicin Delivery to Melanoma Cells: In Vitro Cellular Uptake and Cytotoxicity Studies
Sha Zhong (2009)
Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies.
C. Hu (2014)
Exemestane loaded polymeric nanoparticles for oral delivery
P. Srinivas (2014)See more